The task of informing workers of hazards in theworkplaceisseldommoredifficultthanwith
physicians are faced with a paucity of relevant medical information. Workers, kept aware of the thalidomide spectre with every media report of the latest descriptive epidemiology study, are anxious to know more. Employers, knowing that few agents are regulated on the basis of reproductive hazards, are encouraged to lessen workplace exposure to all agents but need guidance from government and scientists in setting priorities. Understandable ethical and scientific limitations on human studies require researchers to study animals and cells. The difficulties of extrapolating the results of this research to humans are well known. The scientific, medical, and workplace difficulties in dealing with reproductive and developmental hazards are mirrored in the regulatory positions found in North America. Some regard fetal protection policies as sex discrimination whereas others consider such policies as reasonable. Guidelines are provided to allow employers and medical practitioners to consider this difficult problem.
A 26 year old laboratory technician (para 2) presented at eight weeks gestation for advice about workplace health risks to her fetus if she continued work. Two years earlier while employed, she had a stillborn infant at 36 weeks and, as her job remained the same, she was concerned that continuing her work could adversely affect the fetus. Neither she nor her husband had any known risk factors that might affect pregnancy according to an assessment made by her obstetrician.
Worksite evaluation showed good work practices, proper ventilation, and good personal protection. None of the chemicals used were known reproductive hazards. The employer, although reluctant to reassign pregnant employees, was willing to do so if this should be recommended by the employee's doctor.
She discussed the situation with her doctor and the occupational health clinic physician and decided to continue work. At 14 weeks she had a spontaneous abortion and resigned shortly afterwards. She stated that she would not work with chemicals again until she had finished having children. Although she acknowledged that her work likely had nothing to do with the spontaneous abortion, she felt very guilty that she had remained at work. The physicians wondered if they had erred: Had the worksite been properly assessed? Did they have the best available information about potential hazards? The employer also had doubts: Would he have risked being charged with discrimination on the basis of sex ifhe had reassigned this employee? If he had no position to reassign her to, would he have been obliged to put her on paid sick leave even though she was not ill?
Health professionals, particularly family physicians, face one of the most problematical tasks in medicine: assessing and explaining the risk of exposure to a suspect workplace agent when the background (natural) incidence of adverse effect is very high. Each media report' associating a birth defect with yet another workplace or environmental agent revives the spectre of thalidomide. Unfortunately, good science does not ensure that a product falsely labelled as a teratogen (as was Bendectin2) will be acceptable to a public aroused by news media accusations to the contrary.
The dilemma faced by the workers and the physician is mirrored by the employer's enigma. On the one hand he is obliged to provide a safe workplace, but the degree of risk from worker exposure is questionable even Certainly the most significant of these studies is that which associated childhood leukaemia with the fathers' employment at the nuclear plant in Sellafield, England.2 '9 The results of this case-control study are at odds with the much larger study of the children of Japanese men who survived the atomic bomb explosions.'0 If the British study has truly shown a link between childhood leukaemia and the fathers' exposure to ionising radiation, there are great implications for other workplaces and for other agents that damage male germ cells.
Epidemiological studies of exposure to anaesthetic gases and pregnancy outcome" have found an increase in spontaneous abortions among women exposed to these gases in hospitals and dentists' offices. Exposure to anaesthetic gases is frequently higher than expected because of leaks in the equipment and poor maintenance of scavenging systems.'2 Biological monitoring of exposure to nitrous oxide in surgical areas has shown good correlation between the ambient concentrations of nitrous oxide and concentrations of the gas in urine and expired air. Few chemicals can be monitored so readily.
MALE MARKERS
Necessary limitations to carrying out agent effect studies on the human fetus dictate the use of animal subjects to a far greater extent than in virtually any other area of medicine. The same is not true, however, for studies of sperm. Traditional sperm studies, such as sperm count, mobility, and morphology, have historically been subjective measures that vary within each man and considerably among individual subjects.'5 Although oflimited value in the occupational area, they have nevertheless proved useful in the follow up of azospermic and oligospermic workers who had been exposed to 1,2-dibromo-3-chloropropane.""3 The study by Levine et al ofthe sperm of normal men working outdoors in Texas during the summer and winter found changes that may partly explain the deficit of births during the spring season in warm climates. Decreases between 24% and 32% were noted for sperm count, sperm concentration, and concentration of motile sperm in the summer.'3
The use of biomarkers in sperm studies will improve the sensitivity and specificity of measures of physiological and genetic damage.'5 As men account for about 40% of infertility in couples and the extra chromosome in children with Down's syndrome originates with the father in 25-50% of the cases,'5 improved biomarkers of genetic damage in sperm or offspring will greatly improve our understanding of some reproductive and developmental hazards. Meanwhile, in the absence of practical biomarkers, no efficient mammalian tests exist for studying germinal mutations. Instead, germinal mutagenicity is tested in mice: a serious limitation since only about 30 of the 60 000 or more chemicals in the United States and Canada have been studied for germinal mutagenicity.'5 Until practical biomarkers of genetic damage and heritable mutations are developed for the male germ line, hazard identification and risk assessment in the workplace will remain woefully inadequate. This inadequacy is heightened by the fact that the other half of the genetic package of conception, the egg, will never provide the opportunity for studies that are possible with sperm. Because of the necessary restrictions on the study of the human fetus, hazard identification and risk assessment is largely done on animals.'6 The next section reviews significant aspects of animal studies.
Animal toxicological evidence of birth defect hazards Because of the technical and ethical limitations of fetal study, reliance on animal studies to assess reproductive and developmental hazards will be much greater than in most fields of medicine. Studying the human embryo after the appearance of the primitive streak is prohibited in most countries. In fact, pressure exists from some groups to completely prohibit research on fertilised human eggs.'6 The benefits from research using fertilised human eggs and embryos will no doubt justify some research but the controversy will make animal toxicology the likely alternative.
Extrapolating the results of animal reproductive and developmental toxicology to identify human hazards will exceed the well known difficulties in mutagenesis and carcinogenesis when extrapolating from animal research to humans. Exceptions exist, however, as noted in the next section.
CONSIDERATIONS OF PATHOLOGY
Morphologicalfactors Laboratory studies of reproduction in animals have provided much information of benefit to humans; hormonal contraceptive work being a prime example. Animal studies are also the mainstay in the evaluation of possible teratogenic effects of medications, a practice for which there is no present alternative. There are dangers, however, in drawing single conclusions from animal studies, a problem that became evident in the testing of the sedative thalidomide. Mice and rat embryos were not harmed by doses 10 times higher than the clinical and teratogenic dose in human subjects.'6 The tragic results of direct dependence on an animal study have resulted in greater attention to interspecies organogenetic differences.
The commonly used test species, mice and rats, have much shorter periods of organogenesis than humans (table 1) . Hence, the time of exposure to an agent that may cause a developmental effect in a mouse or rodent fetus is crucial because of the brief time (maybe less than a day) during which the developing organ is susceptible. If this susceptible period is missed, say due to a weekend laboratory closure, a positive effect may be missed. Negative results may thus provide false reassurance of the safety of the compound. The mouse cerebellum, for example, is adversely affected by the antimitotic cancer drug 5-azacytidine only by treatment on embryonic day 12.'7 Metabolicfactors Coincident with the morphological changes oforganogenesis are fetal metabolic developments such as the Krebs cycle.'8 Enzyme development is of particular interest because of the role of some enzymes in the activation of chemicals to a toxic form. This phenomenon of metabolic activation is well known in cancer research and is used routinely in the Ames test.
Discovering similar metabolic activation in the fetus has been anticipated, but animal fetuses tend not to have concentrations of activating enzymes as high as those in the human fetus (table 2) .38 Hence, studies ofa possible effect using animals may not be an adequate means of study if metabolic activating enzymes are too low in the animal to produce the toxin. By contrast, the same enzyme in the human fetus could be present at concentrations sufficient to cause damage.
Chromosomal and biochemicalfactors Animal toxicology permits the study of the mechanisms of actions of embryotoxic chemicals. Studies of the fetotoxic effects of 2-methoxyethanol (2-ME) at the Chemical Institute of Industrial Toxicology have shown some interesting malformation attenuating effects of serine in mice. 39 The incidence of digit malformations in near term mouse fetuses is decreased significantly if serine is given to the exposed pregnant mouse. It is hypothesised that the fetotoxic effect of 2-ME is due to impaired purine biosynthesis. Serine may decrease this effect by providing the precursors required in the repair process.
Other animal studies have found unexpected associations between the outcome of pregnancy and biochemical markers. For example, in studying the high incidence of congenital malformations and diabetes, Sadler4' has found that low blood sugar concentrations and ketosis in mice are associated with an increased incidence of malformations in offspring. It remains speculative as to whether similar associations exist in humans. If low blood sugar and ketosis are factors in humans, there could be implications for the management of diabetic patients. No evidence exists yet that other fetal toxins interact in diabetic mice to produce more malformations than either the toxin or the diabetes.
The central nervous system Until recently, studies of fetal central nervous system toxicity were limited to observations of morphological and anatomical changes. Using these measures, researchers identified the emergence of the parts of the central nervous system and the exposure related susceptibility of the developing organ to toxins. Recent progress in cellular and molecular research has provided more sensitive tools for the study of toxins. Early studies of the chronological development of drug binding sites in the fetal rat brain indicate that parallels exist in the emergence and susceptibility of binding sites similar to those of morphological organogenesis.4' Similarly, development of some central nervous system binding sites continues after birth as does the anatomical development of the brain. Figures 2 and 3 (1) Reproductive and developmental policies are discriminatory Any discrimination of an employee on the basis of a sex specific reproductive and developmental policy is characterised at law as prima facie discrimination on the basis of sex and is prohibited by the federal and provincial human rights legislation unless justified by a bona fide occupational qualification. Furthermore, such policies are characterised as discriminatory even if the employer does not intend to discriminate; the mere fact that the policy excludes a group of employees from certain jobs on the basis of sex is enough for a finding of discrimination that must be justified by the bona fide qualification defence.
(2) The bonafide occupational qualification defence A fetal protection policy is justifiable if the employer shows that such discrimination is a bona fide occupational qualification reasonably necessary to the normal operations of the business. The Supreme Court of Canada has held that to be a bona fide occupational qualification, a limitation ". . . must be imposed honestly, in good faith, and in the sincerely held belief that such limitation is imposed in the interests of the adequate performance of the work involved with all reasonable dispatch, safety and economy and not for the ulterior or extraneous reasons aimed at objectives which would defeat the purpose of [human rights legislation]. In addition, it must be related in an objective sense to the performance concerned in that it is reasonably necessary to ensure the efficient and economical performance of the job without endangering the employee, fellow employees and the general public. Justice White listed four reasons why the Johnson Controls policy failed, and in so doing provided some guidance as to when such a policy may succeed.
These reasons were as follows:
(1) Although Johnston Controls showed a high risk that fetal injury would occur in the absence of a fetal protection policy, Johnson Controls failed to consider the extent offetal injury likely to occur. The fetal protection policy would not be a bona fide occupational qualification if it sets a risk-avoidance level substantially higher than other risk levels tolerated by Johnson Controls.
(2) The fetal protection policy of Johnson Controls was too far reaching because it excluded all fertile women regardless of age and excluded women from positions that might lead to a promotion to a position in which there would be a high lead exposure.
(3) Before 1982, Johnson Controls operated without an exclusionary policy; however, it failed to show grounds for now implementing the exclusionary policy-for example, that the risks of fetal harm or the costs associated with fetal harm had substantially increased since 1982.
(4) Johnson Controls should not have succeeded in the lower courts because the lower courts applied the "business necessity" test. This was the wrong test and it improperly placed the burden of proof on the petitioners and not Johnson Controls. The proper test is the bona fide occupational qualification test which places the burden of proof squarely on Johnson Controls. As a result, the lower courts failed to properly consider the petitioners' evidence of harm to offspring caused by exposure to lead in men.
IMPACT OF JOHNSON CONTROLS IN CANADA
The Canadian courts have not yet heard a challenge to an employer's fetal protection policy. Before the Johnson Controls case it appeared that the Canadian courts would have upheld an employer's fetal protection policy as a bona fide occupational qualification, provided that it met certain carefully defined parameters. The Canadian Human Rights Commission has reviewed several claims of discrimination based on fetal protection policies and has allowed the policies to stand when it has been shown that such discrimination is justified by a bona fide occupational qualification defence. The Commission has required statistical and medical evidence of the effect of hazardous substances on the fetus and evidence that no reasonable alternative to the fetal protection policy is available that would not create undue hardship on the employer. The Commission has recommended a variety of settlements depending on the facts in each case. These include reassignment of affected women to less hazardous positions accompanied by remuneration protection, the enforcement of reformed standards including the reduction of exposure levels to protect pregnant women from exposure to hazardous substances and layoffs when available reassignment positions are lacking. This GUIDELINES FOR HEALTH PROFESSIONALS56 57 Health professionals face increasing difficulties in advising patients about continuing work in an environment that is generally considered safe with regard to reproductive and developmental health but in which there are many unknowns. Even in the safest environment, 3-6% of babies will inevitably have a malformation. Parents, particularly mothers, may blame themselves for continuing work that might have contributed to their child's deformity. However minuscule the risk, the mother's doubt and guilt may persist. Doctors and nurses share these anxieties and doubts for they are the principle advisors to the prospective parents and will introspectively wonder if they could have given poor advice through ignorance of the workplace. Health professionals must prepare themselves for this difficult role by learning more about developmental hazards. The high background incidence of anomalies only emphasises the necessity of continued attention to the provision of good prenatal care, a requirement which must include careful consideration of the patient's workplace. 
